Centre Eugène Marquis

Running trials

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Source

• Not yet recruiting

  Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

  NCT07637851· Phase 1/2· Source

• Not yet recruiting

  Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

  NCT07437287· Phase 2/3· Source

• Recruiting

  Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer

  NCT07570524· Source

• Recruiting

  Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

  NCT07043543· Source

• Recruiting

  Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer

  NCT07189598· Source

• Recruiting

  Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

  NCT07122089· Phase 2· Source

• Recruiting

  Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

  NCT06225505· Source

• Recruiting

  ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  NCT07007559· Phase 2· Source

• Recruiting

  Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

  NCT06599879· Source

• Recruiting

  Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

  NCT07195344· Phase 4· Source

• Not yet recruiting

  Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers

  NCT07097064· Phase 2· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Source

• Recruiting

  Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

  NCT06878664· Phase 3· Source

• Recruiting

  Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  NCT06475352· Phase 2· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Active, not recruiting

  Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

  NCT06557889· Phase 2· Source

• Active, not recruiting

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· Phase 3· Source

• Active, not recruiting

  Streamlined Geriatric and Oncological Evaluation Based On IC Technology

  NCT05720910· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· Source

• Recruiting

  Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

  NCT06333314· Phase 2· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Recruiting

  Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

  NCT06211257· Source

• Recruiting

  CARE1 Pragmatic Clinical Trial

  NCT06364631· Phase 3· Source

• Recruiting

  Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

  NCT06027632· Source

• Recruiting

  Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer

  NCT05874492· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· Source

• Active, not recruiting

  EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

  NCT06923761· Phase 1/2· Source

• Recruiting

  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  NCT05786924· Phase 1/2· Source

• Recruiting

  TARGETed Therapy Drug MONITOring in DIGestive Oncology

  NCT05443087· Source

• Recruiting

  Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

  NCT04935853· Source

• Active, not recruiting

  A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

  NCT05050942· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

  NCT04931342· Phase 2· Source

• Recruiting

  Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

  NCT03967834· Source

• Active, not recruiting

  Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

  NCT04794699· Phase 1· Source

• Active, not recruiting

  Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

  NCT03915678· Phase 2· Source

• Active, not recruiting

  Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin

  NCT04536805· Phase 1/2· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

  NCT04524871· Phase 1/2· Source

• Active, not recruiting

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· Phase 3· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· Source

• Active, not recruiting

  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

  NCT04561362· Phase 1/2· Source

• Recruiting

  Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

  NCT03651206· Phase 2/3· Source

• Active, not recruiting

  Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

  NCT04115007· Phase 3· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Source

• Active, not recruiting

  Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

  NCT03870919· Source

• Recruiting

  Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

  NCT03830788· Source

• Active, not recruiting

  Two Chemotherapy Regimens Plus or Minus Bevacizumab

  NCT03351296· Phase 2· Source

• Recruiting

  Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

  NCT02838602· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers6 recruiting
• Sarcoma6 recruiting
• Liver and biliary tract cancer5 recruiting
• Colorectal cancer4 recruiting
• Metastatic breast cancer4 recruiting
• Neuroendocrine tumours4 recruiting
• Ovarian cancer4 recruiting
• Pancreatic cancer4 recruiting
• Prostate cancer3 recruiting
• Triple-negative breast cancer2 recruiting
• Bladder cancer1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Neuroblastoma1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

  NCT06599463· Source

• Withdrawn

  Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

  NCT06084689· Phase 2· Source

• Completed

  Impact of an Educational Physiotherapy-Yoga Intervention on Perceived Stress in Women Treated With Brachytherapy for Cervical Cancer

  NCT06263283· Source

• Completed

  Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

  NCT06660147· Source

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· Phase 2· Source

• Terminated

  Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

  NCT05932667· Phase 2· Source

• Completed

  A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer

  NCT05846594· Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Phase 2· Source

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Source

• Recruiting

  Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

  NCT05378204· Source

• Completed

  Impact of Personalized and Remote Support Centered on Exercise and Physical Activity for Breast Cancer Patients

  NCT04536584· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

  NCT04242199· Phase 1· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Completed

  A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer

  NCT04354233· Source

• Completed

  Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

  NCT04132960· Phase 2· Source

• Completed

  Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

  NCT03726775· Phase 2· Source

• Completed

  Phase II Study of Regorafenib as Maintenance Therapy

  NCT03793361· Phase 2· Source

• Completed

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Source

• Terminated

  Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

  NCT03412058· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Source

• Completed

  A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

  NCT03371017· Phase 3· Source

• Completed

  Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

  NCT03249142· Phase 1/2· Source

• Terminated

  ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

  NCT02933801· Phase 2· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Source

• Completed

  Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

  NCT02676349· Phase 2· Source

• Completed

  Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

  NCT02704832· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Source

• Completed

  PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

  NCT02359968· Phase 2· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Source

• Completed

  Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

  NCT00673335· Phase 3· Source